AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 132 min read$APO

Apollo Global Is Said in Talks to Acquire J&J’s Orthopedics Unit

Apollo Global Management is in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, for around $20 billion. J&J plans to separate the unit, which generated $9.3 billion in sales last year, by mid-2027. Apollo and J&J declined to comment. J&J shares were at $265.58, and Apollo shares rose 0.8% to $128.98.

Original reporting
yahoo.com
Published Sep 13, 2026, 6:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 6:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$APO
Bullish
high confidence
Mentioned
$APO · $JNJ
Relevance
9/10
AlphAI data visualization · based on yahoo.com
Decision brief

The 30-second read

$APOBullishHigh
01

Why it matters

The announced talks represent the first public indication of a concrete deal size and timeline, offering traders a fresh catalyst.

02

Market read

First‑report M&A news with $20 billion valuation, likely to move both Apollo and J&J stocks and affect healthcare M&A sentiment.

03

What to watch

Regulatory scrutiny of large healthcare acquisitions and potential antitrust concerns could delay or block the deal.

Relevance 9/10Novelty 9/10Timing: today

Background

Apollo Global Management has been expanding its healthcare portfolio; J&J announced plans to separate its orthopedics business last year.

Company-level read

Ticker impact

$APOBullishHigh confidence
Context

Apollo Global Management is in talks to acquire Johnson & Johnson's orthopedics unit DePuy Synthes for about $20 billion.

Expected impact

Apollo may rise on deal optimism; J&J could see modest upside or volatility.

Evidence & confidence

Deal size is material and represents Apollo's biggest healthcare bet; market typically reacts to M&A rumors.

$JNJNeutralMedium confidence
Context

Johnson & Johnson is considering selling its DePuy Synthes orthopedics unit, valued near $20 billion.

Expected impact

JNJ may experience slight upside or stability as investors price in potential cash proceeds.

Evidence & confidence

The transaction is still in discussion; market impact depends on final terms and timing.

Market effects

Sector

Healthcare equipment sector may see consolidation pressure; private‑equity interest in medtech rises.

Regional

U.S. markets could see increased activity in healthcare and PE stocks.

Global

Large‑scale cross‑border M&A could influence global healthcare M&A sentiment.

Counterpoint

What could challenge this read

Deal may fall apart, leaving Apollo with sunk due‑diligence costs and J&J may pursue a spin‑off instead.

Key entities

  • Company
    Apollo Global Management Inc.

    Alternative asset manager pursuing acquisition.

  • Company
    Johnson & Johnson

    Pharma and medical‑technology conglomerate considering divestiture.

  • Business Unit
    DePuy Synthes

    J&J's orthopedics division targeted for sale.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 11
$JNJMedAI 8/10

Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports

Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, for around $20 billion. The unit, which generated $9.3 billion in sales in 2025, is planned to be separated into a standalone company. Bloomberg News cited sources for the report, but Reuters could not verify it. J&J and Apollo Global Management did not comment.

investing.com1 min
SEP 11
$JNJMedAI 9/10

Meet Ottava, J&J's surgical robot leading the healthcare giant into a lucrative new market

Johnson & Johnson's Ottava surgical robot received FDA approval for general surgery procedures. The company aims to compete with Intuitive Surgical's da Vinci system, leveraging its existing surgical tools and operating room presence. J&J projects significant growth in the robotic surgical market, with global expansion expected to reach $50.29 billion by 2035. The company's MedTech segment, including surgery, is projected to be roughly a third of J&J's sales this year. Ottava is currently approv

cnbc.com3 min
SEP 11
$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

rttnews.com3 min
SEP 10
$JNJMed

JNJ Maintains Buy Rating by HSBC -- Price Target Raised to $320

HSBC maintained a Buy rating on Johnson & Johnson (JNJ) and raised its price target to $320 from $290, citing a strong product pipeline and strategic focus. JNJ's stock is trading at $268.82, which is 39.2% overvalued according to its GF Value™ of $193.18. The company has a GF Score™ of 83/100, indicating strong overall performance, but shows significant insider selling.

gurufocus.com2 min